Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering Plough’s Bridion Faces FDA Setback

This article was originally published in The Pink Sheet Daily

Executive Summary

Safety concerns render anesthesia injection “not approvable” in U.S.

You may also be interested in...



Sugammadex Review: Has Merck Finally Put Safety Concerns To Rest?

Adequacy of data on risks of hypersensitivity/anaphylaxis and cardiac dysrhythmia with neuromuscular blockade reversal agent are focus of FDA advisory committee review.

Merck Comes Prepared This Time As Sugammadex Faces Second Advisory Committee

After failing to submit safety data on time during the drug’s first FDA review, Merck has its data together and is armed with a new hypersensitivity study in advance of the second panel review for its anesthesia product.

Schering Plans Bridion Clinical Trial To Address FDA’s Hypersensitivity Concerns

Company expects to initiate the trial for the novel anesthesia injection this year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel